** 23andMe, the once-popular genetic-testing company that recently filed for bankruptcy, has struck a deal to sell its massive DNA database—previously holding info from 15 million customers—to biotech giant Regeneron for $256 million. Essentially, your spit kit data is changing hands.

What This Mean: ** This isn’t just a corporate fire sale—it’s a big shift in who controls a treasure trove of genetic data. Regeneron, which develops drugs using genetic insights, could mine this info for future treatments. But it also raises questions: What happens to privacy promises made to 23andMe customers? And will this deal set a precedent for other struggling health-tech firms? Either way, your DNA might end up doing more than just tracing your ancestry.

Drug giant Regeneron is swooping in to buy the struggling DNA-testing company 23andMe for $256 million as it files for bankruptcy. While this saves the once-hot startup from collapse, it also means Regeneron now gets access to the genetic data of millions of 23andMe customers—raising big questions about privacy and how that sensitive info might be used.

What This Mean: This isn’t just another corporate buyout—it’s a deal that could reshape who controls your DNA. 23andMe’s downfall is a cautionary tale about the shaky business of consumer genetics, but the real story here is what happens next. With Regeneron holding the keys to a massive genetic database, patients and privacy advocates are right to ask: Who’s really benefiting from this data, and at what cost?